{"name":"Acerta Pharma BV","slug":"acerta-pharma-bv","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"ACP-196","genericName":"ACP-196","slug":"acp-196","indication":"Chronic lymphocytic leukemia","status":"phase_2"},{"name":"AZD9150","genericName":"AZD9150","slug":"azd9150","indication":"Advanced solid tumors, including lymphoma and multiple myeloma","status":"phase_2"},{"name":"Acalabrutinib (ACP-196)","genericName":"Acalabrutinib (ACP-196)","slug":"acalabrutinib-acp-196","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"Acalabrutinib in combination with BR","genericName":"Acalabrutinib in combination with BR","slug":"acalabrutinib-in-combination-with-br","indication":"Chronic lymphocytic leukemia","status":"phase_1"},{"name":"Acalabrutinib in combination with VR","genericName":"Acalabrutinib in combination with VR","slug":"acalabrutinib-in-combination-with-vr","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_1"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ACP-319","genericName":"ACP-319","slug":"acp-319","indication":"Other","status":"phase_1"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"AZD5153","genericName":"AZD5153","slug":"azd5153","indication":"Relapsed or refractory hematologic malignancies","status":"phase_1"}]}],"pipeline":[{"name":"ACP-196","genericName":"ACP-196","slug":"acp-196","phase":"phase_2","mechanism":"BTK inhibitor","indications":["Chronic lymphocytic leukemia"],"catalyst":""},{"name":"ACP-319","genericName":"ACP-319","slug":"acp-319","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5153","genericName":"AZD5153","slug":"azd5153","phase":"phase_1","mechanism":"AZD5153 is a selective BET bromodomain inhibitor that disrupts the interaction between bromodomains and acetylated histones, leading to changes in gene expression.","indications":["Relapsed or refractory hematologic malignancies"],"catalyst":""},{"name":"AZD9150","genericName":"AZD9150","slug":"azd9150","phase":"phase_2","mechanism":"AZD9150 is an antisense oligonucleotide that targets the RNA of the MYC oncogene, leading to reduced expression of MYC protein.","indications":["Advanced solid tumors, including lymphoma and multiple myeloma"],"catalyst":""},{"name":"Acalabrutinib (ACP-196)","genericName":"Acalabrutinib (ACP-196)","slug":"acalabrutinib-acp-196","phase":"phase_3","mechanism":"Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)","Mantle cell lymphoma (MCL)"],"catalyst":""},{"name":"Acalabrutinib in combination with BR","genericName":"Acalabrutinib in combination with BR","slug":"acalabrutinib-in-combination-with-br","phase":"phase_1","mechanism":"BTK inhibitor","indications":["Chronic lymphocytic leukemia","Mantle cell lymphoma"],"catalyst":""},{"name":"Acalabrutinib in combination with VR","genericName":"Acalabrutinib in combination with VR","slug":"acalabrutinib-in-combination-with-vr","phase":"phase_1","mechanism":"BTK inhibitor","indications":["Chronic lymphocytic leukemia (CLL)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQUnZDUV9wRFUwZDFMMUZRcV9FRVpUZGl3MXVTdF9mNW1GVFVFdk4tYmoyM2EtTDNPel9SOW82eEJNWVhNU2trLWRUQkU4WjdnRzNvcXlsNG5zMTdocUpDazJFSE5sTTZ5aDNPYTJSOUpJbmxzRl9uOE1wNmFVelVPY2M5akY1LVRfYUc4S2tFZFk3T0xvZ0pXeVloTk9CTEU?oc=5","date":"2024-11-15","type":"deal","source":"BioWorld News","summary":"Vitalli terminates $477M Daewoong deal, retains $941M option - BioWorld News","headline":"Vitalli terminates $477M Daewoong deal, retains $941M option","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNYl9nUVA2MDVPUk1nMUhMcEI1MUg5bGFTWVBCSFhyeFlQTFhzU3djaUFZVUp2MnR4RnZDWmNCZms3bmMxNGdnbWNhTFlSMHhNYllZRDhVM0VZSzl0S0hQZUZGMndaa0hlRElDcEszZnRDVXZTMUtUZGplNlhXTXJKQ3JMTlgxUWlYS1FTbXpKTGJPdDN5QmRxMWV5TGJEb1RrSjJr?oc=5","date":"2023-02-10","type":"regulatory","source":"Hematology Advisor","summary":"Clinical Trials Testing Novel Combinations in Diffuse Large B-Cell Lymphoma - Hematology Advisor","headline":"Clinical Trials Testing Novel Combinations in Diffuse Large B-Cell Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPbkc3V2F6TDBQbmItOTFTRGpzOVo4bWVKN0dRbmNMSGVza2Z3WHVrWFVWdTFTdTN6cnNKcnp4bGZUYW5zUGNQLTJ2SjU1alozSzRTakhUNEpwdGZyYkx5bE9JY0RhR2lVLUdGYjVXcUlzMUZWdmxKN3JFeEJWU2Zwakdoa1NfRzRIWEpsR1l5anBtdWZnejlIN2NyMnZWNzlyTFlqUkNjU0V4ODE0Z2c?oc=5","date":"2021-10-12","type":"trial","source":"Nairametrics","summary":"AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19 - Nairametrics","headline":"AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBfanBKbjBlM196aGY1Y0IxdTVjR1hPazVHVlFsbEpIcUlIc19EVFpFMmZvNWlzX29BTTlaZTFXUzhrNXBIamJEMmczYkd5VjZFN3JyeVBzdw?oc=5","date":"2016-07-28","type":"pipeline","source":"Forbes","summary":"James Topper - Forbes","headline":"James Topper","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPMHdmQzhTYUYzQ3hESERsRGQ3ZzI0cjB5alI0QXNEcE9oT1lKcG9WcGtveXhwMzRUOUVPenBWZ29jWUxJczU0M3NWTTVaQ3FRMlBUWlBqZHAyd3lLNndFcmVLUVZyVlVEWWhuU01PN1dnVEE3WFpPOVhzMm5OaFROcjBWWTJpdEZkeVlaamVLQndUTU9DWnk3b1RUWkE2YUUtNlNuU3hQa3Q5bWFQUG80cjhyWVNpZVh4ZVNJNUdIbWlwY1pvYlNZZjRDZU5VSGVVWFFmNHhNQzlwZlFRcU1mMTJ3?oc=5","date":"2016-02-25","type":"pipeline","source":"AstraZeneca","summary":"acalabrutinib recommended for orphan drug designation in Europe for three indications - AstraZeneca","headline":"acalabrutinib recommended for orphan drug designation in Europe for three indications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxONmItNFp5NUJaODVkZS0xQUcyZDR0VndITHVHU3JodmlxeTBZQ2J6b01wdUpQd0RkUzc0Qkh6VkFlRzF6WkZxOXJqakpmOEwtellhdXFCTHZOaUgxTWdBenBHY1ZZWGR6SEU0WGI0cXRObnEyWjZnWDl6ZDdDU0FMNlNERTJHNkpLS2lPTmxzSDFGNVFEanFLOEZoR3R5WlpscDRnTHBlaS1vVkNyek8xeXM5RXZlOFN0a0VsQldiOFhXcF96R1ZMYmlfYlk1a19UV1JkMGZXOXRkVjFyU0JfQ0lLYVdzdll2U1ZyMFRQdGhTOGc1?oc=5","date":"2016-02-02","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca completes transaction for majority equity stake investment in Acerta Pharma - AstraZeneca","headline":"AstraZeneca completes transaction for majority equity stake investment in Acerta Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOckYtUjdHNVByR1pkeTRvYU9YMjVoUDltYUdONmFRTldOeEhFdVRMQlZqSG9tOF9IVDRfUHZLV2cteGxBMktXRUI2NmhnejRZck9GVFZhNG8xTDJacWQ0b1JOTS1sTGlhMHdpdTBsdUU0MnF1NW01OGFkbElld3p1OVRwSy1ocjlzUXBnUmJubjRkbG84d0RXb0NYZHY1X2UwLXNURUd1XzdCeUNnRU9WWGJmMy1rcDg2R2d5QXBFUnRPQlNzb3NxUFJTMXBaNzJ6TjNHdkxKbFk4bXpGUzNSdzlB?oc=5","date":"2015-12-17","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma - AstraZeneca","headline":"AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPczlRTE1HMnM0X1VKelY3QmFSUGdobTBQbW8wNHcwTm9IX1VPYmVLZm9yeW5EVVB5c0hnT0dxY19GS01HTW9OZnRDWU1yM1JJcWRJVTNmSklLVlpoNVphR0VPNEcyMVRGajdfVlZ0bjlCOWRVQmZHV21nREtRMWl5ekFxdmQyYTd4ajZ0enNreFFuZUdxcGxkUzVWU1YxWGJLUENhRERnbC1Ya0ZTYXpkajd0VTUxNmZjV2JtZg?oc=5","date":"2015-12-17","type":"deal","source":"Reuters","summary":"AstraZeneca buys most of Acerta for $4 billion to add cancer drug - Reuters","headline":"AstraZeneca buys most of Acerta for $4 billion to add cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOVUNXVkJFV0hlY2ZhWVZ2b0lid2ZtT3lhV2FxeWNOQklyd0FtbWhFYkpxM1cyUFZDOWs0aS1KblNWa1VNMnNuNHVudG9QUmZkMzBEZFZOVkdaTmladHhYYWRMZS1BbGVCSlJiMTE5UXdwamFGRXl4bXREVzAzMl9BWUVNejlWaGpqYkkxSUJNd1poY1BPakZ1eFVSWVZmN2VWV0xBS0FR?oc=5","date":"2015-12-11","type":"deal","source":"wsj.com","summary":"AstraZeneca in Talks to Buy Cancer Drug Developer Acerta Pharma - wsj.com","headline":"AstraZeneca in Talks to Buy Cancer Drug Developer Acerta Pharma","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_2":2,"phase_1":4,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}